Next Article in Journal
Triple Network Resting State Connectivity Predicts Distress Tolerance and Is Associated with Cocaine Use
Next Article in Special Issue
Impact of A Six Week Training Program on Ventilatory Efficiency, Red Blood Cell Rheological Parameters and Red Blood Cell Nitric Oxide Signaling in Young Sickle Cell Anemia Patients: A Pilot Study
Previous Article in Journal
TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients
Previous Article in Special Issue
Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study
Open AccessArticle

International Differences in Outpatient Pain Management: A Survey of Sickle Cell Disease

1
Department of Pediatric Hematology-Oncology, Virginia Commonwealth University, Richmond, VA 23219, USA
2
Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC 29425, USA
3
Department of Medicine, University of Alabama, Birmingham, AL 35233, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(12), 2136; https://doi.org/10.3390/jcm8122136
Received: 29 September 2019 / Revised: 22 November 2019 / Accepted: 29 November 2019 / Published: 3 December 2019
Vaso-occlusive pain crises are the hallmark of sickle cell disease (SCD) and the primary reason for health care utilization. Both national and international guidelines recommend aggressive intravenous opioids, intravenous fluids and anti-inflammatory therapy as the mainstay of treatment for acute SCD pain. However, many vaso-occlusive crises are managed at home with oral medication and supportive care. There are no guidelines on home medication management of SCD-related pain, likely due to the lack of well-defined endpoints for acute events and the lack of funding for already approved pain medications. Amplifying this issue is the growing concern for opioid abuse and misuse in the United States (US) and internationally. This study aimed to evaluate differences in opioid prescribing practices among providers treating SCD in the US and internationally. A survey was disseminated electronically to known providers using a combination of purposive and snowball sampling strategy. There were 127 responses and 17 countries represented. US providers were more likely to prescribe opioids (p < 0.001) and were more likely to be “very comfortable” prescribing opioids than non-US prescribers (p < 0.001). US providers also tended to prescribe more tablets per patient of stronger opioids than non-US physicians. US physicians were more likely to be concerned that patients were abusing opioids than non-US physicians (32% vs. 27%, p < 0.05). There are significant variations in how different parts of the world manage pain in the outpatient setting for SCD. Identifying optimal home pain management strategies is necessary to improve care and long-term outcomes in SCD.
Keywords: sickle cell; opioid; chronic pain sickle cell; opioid; chronic pain
MDPI and ACS Style

El-Amin, N.; Nietert, P.; Kanter, J. International Differences in Outpatient Pain Management: A Survey of Sickle Cell Disease. J. Clin. Med. 2019, 8, 2136.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop